{"organizations": [], "uuid": "69648103cb09cea5448b5e485bc67b39e6f242ec", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-nymox-announces-us-nda-for-fexapot/brief-nymox-announces-u-s-nda-for-fexapotide-for-bph-idUSFWN1PV16Y", "country": "US", "domain_rank": 408, "title": "BRIEF-Nymox Announces U.S. NDA For Fexapotide For BPH", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-05T20:18:00.000+02:00", "replies_count": 0, "uuid": "69648103cb09cea5448b5e485bc67b39e6f242ec"}, "author": "", "url": "https://www.reuters.com/article/brief-nymox-announces-us-nda-for-fexapot/brief-nymox-announces-u-s-nda-for-fexapotide-for-bph-idUSFWN1PV16Y", "ord_in_thread": 0, "title": "BRIEF-Nymox Announces U.S. NDA For Fexapotide For BPH", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "bph reuters", "sentiment": "negative"}, {"name": "brief-nymox announces u.s. nda", "sentiment": "negative"}, {"name": "nda", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "nymox pharmaceutical corp", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "nymox", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 5, 2018 / 6:18 PM / in 32 minutes BRIEF-Nymox Announces U.S. NDA For Fexapotide For BPH Reuters Staff \nFeb 5 (Reuters) - Nymox Pharmaceutical Corp: * NYMOX ANNOUNCES US NDA FOR FEXAPOTIDE FOR BPH \n* SAYS ‍RECENTLY HAD A PRE-NDA MEETING WITH FDA; NDA FOR FEXAPOTIDE FOR BPH​ WILL BE SUBMITTED LATER IN 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-05T20:18:00.000+02:00", "crawled": "2018-02-05T20:45:21.027+02:00", "highlightTitle": ""}